eMedicine Specialties > Cardiology > Congenital Heart Disease in the Adult

Atrial Septal Defect: Treatment

Author: Bekir Hasan Melek, MD, Assistant Professor of Clinical Medicine, Department of Medicine, Section of Cardiology, Tulane University School of Medicine
Coauthor(s): James V Talano, MD, MM, FACC, Director of Cardiovascular Medicine, SWICFT Institute; Jeffrey C Milliken, MD, Chief, Division of Cardiothoracic Surgery, University of California at Irvine Medical Center; Clinical Professor, Department of Surgery, University of California at Irvine School of Medicine; Peter B Smulowitz, BA, University of California at Irvine School of Medicine
Contributor Information and Disclosures

Updated: Jul 11, 2006

Treatment

Medical Therapy

ASD is a surgical disorder, and no specific medical therapy is available. However, patients with CHF may require digitalis and diuretics, and those with arrhythmias may require specific drug therapy.

Surgical Therapy

Criterion standard

The criterion standard in the treatment of ASD is direct closure of the defect by using an open approach with extracorporeal support. John Gibbon performed the first successful ASD closure by applying this method in 1953. Surgical techniques and equipment have since improved to the point that the mortality rate from this repair approaches zero.

In the usual procedure, a median sternotomy incision is made, and the sternum is split in the midline. Direct arterial and double venous (superior vena cava and inferior vena cava) cannulation are performed. By applying cardiopulmonary bypass, the aorta is clamped, and the heart is arrested with a cardioplegia solution. The caval snares are tightened, and the right atrium is opened. Most secundum defects can be closed by using a direct continuous suture of 3-0 or 4-0 polypropylene (Prolene).

Caution must be taken when large defects are directly closed because this closure can distort the atrium. Large defects that rise superiorly can distort the aortic anulus if closed directly. These ASDs are also best closed by using autologous pericardium or synthetic patches made of polyester polymer (Dacron) or polytetrafluoroethylene (PTFE). Care must be taken to completely remove any air or debris from the left atrium and ventricle before cardiopulmonary bypass is discontinued. Temporary pacing wires are left in place on the right ventricle before the chest is closed over the drains.

In patients with ostium primum defects, surgical closure is relatively complicated. The patch must be attached to the septum at the juncture of the mitral and tricuspid valves. Mitral valve repair, including closure of the cleft mitral leaflet and, possibly annuloplasty, may be necessary to correct or prevent mitral insufficiency. In rare cases, mitral valve replacement may be required.

In sinus venosus defects, partial anomalous pulmonary venous return is typical. One or more of the pulmonary veins primarily drains into the right atrium. The ASD must be patched in such a way as to ensure that the anomalous pulmonary venous drainage is diverted into the left atrium. This patching may be simple or complex, depending on where the anomalous drainage enters. Many innovative techniques have been developed to redirect pulmonary flow, and the surgeon should be familiar with several approaches. Pulmonary venous return must not be compromised with the redirection because this invariably causes localized venous hypertension and pulmonary complications.

Minimally invasive approaches

In recent years, minimally invasive approaches to the repair of ASD have garnered significant interest. In most cases, the size of the incision is simply decreased with different approaches to cardiopulmonary bypass. Examples include partial or full submammary skin incision, hemisternotomy, and limited thoracotomy. The goal is to improve better cosmetic results because these approaches are not associated with decreased morbidity or mortality.

Percutaneous transcatheter closure

In recent times, ASDs have been closed by using a variety of catheter-implanted occlusion devices rather than by direct surgical closure with cardiopulmonary bypass. These devices are placed through a femoral venous approach and are deployed like an umbrella to seal the septal defect. These devices work best for small, centrally located secundum defects. Although surgical closure is associated with low morbidity and mortality and excellent long-term results, sternotomy and cardiopulmonary bypass are required.

Drs King and Mills performed the first transcatheter closure of a secundum ASD in the mid-1970s. William Rashkind pioneered the development of percutaneous ASD closure technique in late 1970s. Jim Lock developed the clamshell method in 1989. Around the same time, Sideris started clinical trials with buttoned device.

Although many devices have been studied, over the last few years, 4 major devices have become available: CardioSEAL (NMT Medical, Inc, Boston, Mass), Amplatzer septal occluder (ASO) (AGA Medical Corporation, Golden Valley, Minn), HELEX septal occluder (Gore Medical [WL Gore & Associates, Inc], Flagstaff, Ariz), and Sideris patch (Custom Medical Devices, Amarillo, Tex). The ASO is currently the most widely used device because it is easy to implant and because it allows closure of large orifices with excellent success rates in most cases. It was first used in human in 1995. Selection of a particular device is difficult because no randomized trials have been conducted. Furthermore, devices are currently not amenable to percutaneous closure of ostium primum and sinus venosus defects.

With this technique, the static diameter of the defect is first assessed by using TEE first, and the stretched diameter is then measured with a sizing balloon to select the proper diameter of the device. The margins of the orifice must be wide enough to accommodate the edges of the closing device. TEE has been the mainstream technique for device sizing, positioning, and deployment, but it can cause discomfort. In addition, airway protection and general anesthesia are required. Intracardiac echocardiography was recently found to be superior for the same purposes and has largely replaced TEE.

Transcatheter closure of ASDs is now established practice at most cardiac centers. It is proven safe in experienced hands, it is cost-effective, and it favorably compares to surgical closure with successful implantation rates of >96%. One group compared the surgical technique and percutaneous transcatheter technique for ASD closure in 91 children. Closure rates were similar (95% in the surgery group, 97% in the percutaneous group); however, the transcatheter group had fewer complications, shortened hospitalization, and reduced need for blood products.

Furthermore, transcatheter appears to have additional benefits regarding hemodynamic improvement compared with surgery. In 1 study, transcatheter closure with ASO improved the left atrial volume index, the left ventricular myocardial performance index, and the right ventricular myocardial performance index. The last was unimpressive after surgery, possibly because of cardiopulmonary bypass.

Another group compared atrial function in 45 patients with mean age of 9 years after surgery and after percutaneous closure by using strain-rate imaging. They found that both atrial functions were preserved after transcatheter closure, whereas the same was not seen after surgery. A potential explanation was that an atriotomy scar might have negatively influenced right atrial functio, whereas perioperative hypoxia o intraoperative myocardial damage might have altered the deformation properties of the left atrium.

Postoperative Details

Postoperative management after ASD repair is usually standard. Patients are expected to be awake and are extubated shortly after the operation. Drainage tubes are removed from the chest the first morning after surgery, and, except when rhythm problems occur, the pacing wires are removed shortly thereafter. Most patients can eat and ambulate without difficulty on the first or second postoperative day, and most are discharged by the third or fourth postoperative day. After transcatheter occlusion, 6 months of treatment with aspirin with or without clopidogrel is recommended to prevent thrombus formation.

Follow-up

Surgical follow-up care is maintained until the patient's wounds are completely healed and normal activities are resumed. This period rarely exceeds 1-2 months. All complications must be clearly resolved before the patient is discharged from surgical care.

Obtain at least 1 follow-up echocardiogram to confirm complete closure of the ASD. A pediatric cardiologist should continue patient care to monitor for recurrence of the shunt and to ensure that the patient has returned to normal activities and cardiac function. For most patients, a yearly appointment after the immediate postoperative period is adequate.

For excellent patient education resources, visit eMedicine's Heart Center. Also, see eMedicine's patient education article Palpitations.

Complications

Surgery may be associated with a long-term risk of atrial fibrillation or flutter. The risk of infective endocarditis is highest during the first 6 months after surgery. The following complications are also associated with ASDs:

  • Congestive heart failure
  • Arrhythmias
  • Pulmonary hypertension
  • Cyanosis
  • Paradoxical embolization
  • Stroke
  • Infective endocarditis

The following complications are associated with the use of transcatheter occlusion devices:

  • Device embolization and malpositioning: The incidence significantly varies among devices and is related to operator experience and appropriate case selection. With experienced clinicians, the incidence is <1%. Device embolization and malpositioning happens as a result of inadequate sizing of the defect or incorrect device placement.
  • Postimplantation arrhythmias: The incidence is 1-4% and varies from first- to third-degree AV block and atrial fibrillation. These arrhythmias are usually short-lived and do not require medical treatment. Patients who develop complete heart block are typically hemodynamically stable and do not require pacing. Complete heart block is most common with ASO and has been transient in all cases. The incidence of arrhythmia appears to be related to the size of the device.
  • Thrombus formation: A study of 1000 patients was done to investigate the incidence of thrombus by performing TEE at 4 weeks and 6 months after the procedure. The overall incidence was 1.2%; 70% were found at 4 weeks. The lowest incidence was with ASO. Thromboembolic events were seen in 20% of patients with thrombus. In 80-85%, thrombus resolved with heparin and warfarin. Risk factors for thrombogenesis on the device were the type of device, postprocedural atrial fibrillation, incomplete neoendothelialization of the surface of the device, insufficient antithrombotic treatment, and previously undiagnosed hypercoagulability disorders (including aspirin resistance and persistent interatrial septal aneurysm). For prophylaxis, aspirin given for 6 months is a common practice. When combined with clopidogrel, no thrombus was noted at 4 weeks and 6 months in 1 study of 37 patients.
  • Cardiac perforation: the incidence is 0.1-0.4% for various devices. Oversizing of the device and deficient anterosuperior rims are risk factors for perforation. Technique-related perforation during the procedure is amenable to intervention. Device-related perforations occur after technically adequate procedure in approximately 70% of patients after hospital discharge. A retrospective review of 24 patients revealed that all presented with chest pain, shortness of breath, hemodynamic collapse or sudden death. About 76% were female patients, and 70% of the perforations were late. If pericardial effusion is present on predischarge echocardiography, hospitalize the patient for 24-48 hours of observation and follow-up echocardiography.
  • Device erosion: Erosion of septal occluder devices occurs in 0.1-0.15% of implants. Nearly all erosions occur at the dome of atria near the aortic root. Risk factors are a deficient aortic rim and/or superior rim and use of an oversized device. Aortic – right atrial fistula may be the consequence. Although device erosion is rare, the mortality rate is 10%.
  • Increased levels of cardiac troponin I: Transcatheter closure induces minor myocardial lesions, the extent of which depends on the size of the ASO. The patient's age is not a factor.
  • Residual shunts: As many as 25% of patients may have a residual shunt after the procedure; >90% of such residua are small. During follow-up, the incidence drops to 10% at 1 month, 1% at 1 year, and 0% at 3 years.
  • Relatively common complications: Other complications include pericardial effusion, transient ischemic attack, and sudden death.

More on Atrial Septal Defect

Overview: Atrial Septal Defect
Workup: Atrial Septal Defect
Treatment: Atrial Septal Defect
Follow-up: Atrial Septal Defect
References

References

  1. Amin Z, Hijazi ZM, Bass JL, et al. Erosion of Amplatzer septal occluder device after closure of secundum atrial septal defects: review of registry of complications and recommendations to minimize future risk. Catheter Cardiovasc Interv. Dec 2004;63(4):496-502.

  2. Anzai H, Child J, Natterson B, et al. Incidence of thrombus formation on the CardioSEAL and the Amplatzer interatrial closure devices. Am J Cardiol. Feb 15 2004;93(4):426-31.

  3. Argenziano M, Oz MC, DeRose Jr JJ, et al. Totally endoscopic atrial septal defect repair with robotic assistance. The Heart Surgery Forum. 2001;5(3):[Full Text].

  4. Bartel T, Konorza T, Arjumand J, et al. Intracardiac echocardiography is superior to conventional monitoring for guiding device closure of interatrial communications. Circulation. Feb 18 2003;107(6):795-7. [Medline].

  5. Bartel T, Konorza T, Neudorf U. Intracardiac echocardiography: an ideal guiding tool for device closure of interatrial communications. Eur J Echocardiogr. Mar 2005;6(2):92-6.

  6. Bedford D. The anatomical types of atrial septal defect. Their incidence and clinical diagnosis. Am J Cardiol. 1960;6:568.

  7. Besterman E. Atrial septal defect with pulmonary hypertension. Br Heart J. 1961;23:587-98.

  8. Bialkowski J, Karwot B, Szkutnik M, et al. Closure of atrial septal defects in children: surgery versus Amplatzer device implantation. Tex Heart Inst J. 2004;31(3):220-3.

  9. Braunwald E. Atrial Septal Defect. In: Braunwald E, ed. Heart Disease: A Text of Cardiovascular Medicine. 4th ed. Philadelphia, Pa: WB Saunders;1992:906-8.

  10. Carlsson E. Anatomic diagnosis of atrial septal defects. Am J Roentgenol Radium Ther Nucl Med. Jun 1961;85:1063-70.

  11. Cherian G, Uthaman CB, Durairaj M, et al. Pulmonary hypertension in isolated secundum atrial septal defect: high frequency in young patients. Am Heart J. Jun 1983;105(6):952-7. [Medline].

  12. Chessa M, Carminati M, Butera G, et al. Early and late complications associated with transcatheter occlusion of secundum atrial septal defect. J Am Coll Cardiol. Mar 20 2002;39(6):1061-5. [Medline].

  13. Di Salvo G, Drago M, Pacileo G, et al. Atrial function after surgical and percutaneous closure of atrial septal defect: a strain rate imaging study. J Am Soc Echocardiogr. Sep 2005;18(9):930-3.

  14. Divekar A, Gaamangwe T, Shaikh N, et al. Cardiac perforation after device closure of atrial septal defects with the Amplatzer septal occluder. J Am Coll Cardiol. Apr 19 2005;45(8):1213-8.

  15. Goldman L, Braunwald E. Primary Cardiology. Philadelphia, Pa: WB Saunders;1998:394-411.

  16. Holmvang G, Palacios IF, Vlahakes GJ, et al. Imaging and sizing of atrial septal defects by magnetic resonance. Circulation. Dec 15 1995;92(12):3473-80. [Medline].

  17. Isselbacher KJ, Braunwald E, Wilson JD. Atrial septal defect In: Isselbacher KJ, ed. Harrison's Principles of Internal Medicine. 13th ed. New York, NY: McGraw-Hill;1994:1041.

  18. Jost CH, Connolly HM, Danielson GK, et al. Sinus venosus atrial septal defect: long-term postoperative outcome for 115patients. Circulation. Sep 27 2005;112(13):1953-8.

  19. Kirklin JW, Barratt-Boyes BG. Cardiac Surgery. London, England: Churchill Livingstone; 1986: 463-97.

  20. Konstantinides S, Geibel A, Olschewski M, et al. A comparison of surgical and medical therapy for atrial septal defect in adults. N Engl J Med. Aug 24 1995;333(8):469-73. [Medline].

  21. Kronzon I, Tunick PA, Freedberg RS, et al. Transesophageal echocardiography is superior to transthoracic echocardiography in the diagnosis of sinus venosus atrial septal defect. J Am Coll Cardiol. Feb 1991;17(2):537-42. [Medline].

  22. Krumsdorf U, Ostermayer S, Billinger K, et al. Incidence and clinical course of thrombus formation on atrial septal defect and patient foramen ovale closure devices in 1,000 consecutive patients. J Am Coll Cardiol. Jan 21 2004;43(2):302-9.

  23. Latson LA. Per-catheter ASD closure. Pediatr Cardiol. Jan-Feb 1998;19(1):86-93; discussion 94. [Medline].

  24. Marelli AJ, Moodie DS, Topol EJ. Adult congenital heart disease. In: Textbook of Cardiovascular Medicine. Philadelphia, Pa: Lippincott-Raven; 1998: 775-9.

  25. Masura J, Gavora P, Podnar T. Long-term outcome of transcatheter secundum-type atrial septal defect closure using Amplatzer septal occluders. J Am Coll Cardiol. Feb 15 2005;45(4):505-7.

  26. Moore KL, Persaud TVN. Before We Are Born: Essentials of Embryology and Birth Defects. Philadelphia, Pa: WB Saunders Co; 1998: 774-7.

  27. Murphy JG, Gersh BJ, Mair DD, et al. Long-term outcome in patients undergoing surgical repair of tetralogy of Fallot. N Engl J Med. Aug 26 1993;329(9):593-9. [Medline].

  28. O''Laughlin MP. Catheter closure of secundum atrial septal defects. Tex Heart Inst J. 1997;24(4):287-92. [Medline].

  29. Piechaud JF. Closing down: transcatheter closure of intracardiac defects and vessel embolisations. Heart. Dec 2004;90(12):1505-10.

  30. Rao PS. Catheter closure of atrial septal defects. J Invasive Cardiol. Jul 2003;15(7):398-400. [Medline].

  31. Ruge H, Wildhirt SM, Libera P, et al. Images in cardiovascular medicine. Left atrial thrombus on atrial septal defect closure device as a source of cerebral emboli 3 years after implantation. Circulation. Sep 6 2005;112(10):e130-1.

  32. Salehian O, Horlick E, Schwerzmann M, et al. Improvements in cardiac form and function after transcatheter closure of secundumatrial septal defects. J Am Coll Cardiol. Feb 15 2005;45(4):499-504.

  33. Sealy WC, Farmer JC, Young Jr WG, et al. Atrial dysrhythmia and atrial secundum defects. J Thorac Cardiovasc Surg. Feb 1969;57(2):245-50. [Medline].

  34. Seward JB, Khandheria BK, Edwards WD, et al. Biplanar transesophageal echocardiography: anatomic correlations, image orientation, and clinical applications. Mayo Clin Proc. Sep 1990;65(9):1193-213. [Medline].

  35. Staniloae CS, El-Khally Z, Ibrahim R, et al. Percutaneous closure of secundum atrial septal defect in adults a single center experience with the amplatzer septal occluder. J Invasive Cardiol. Jul 2003;15(7):393-7. [Medline].

  36. Stark J. Secundum atrial septal defect. In: Surgery for Congenital Heart Defects. New York, NY: Grune & Stratton; 1983.

  37. Tardif JC, Schwartz SL, Vannan MA, et al. Clinical usefulness of multiplane transesophageal echocardiography: comparison to biplanar imaging. Am Heart J. Jul 1994;128(1):156-66. [Medline].

  38. Tarnok A, Bocsi J, Osmancik P, et al. Cardiac troponin I release after transcatheter atrial septal defect closure depends on occluder size but not on patient''s age. Heart. Feb 2005;91(2):219-22.

  39. Thuny F, Di Salvo G, Disalvo G, et al. Risk of embolism and death in infective endocarditis: prognostic value of echocardiography: a prospective multicenter study. Circulation. Jul 5 2005;112(1):69-75.

  40. Tonni G, Ferrari B, Defelice C, Centini G. Neonatal porencephaly in very low birth weight infants: Ultrasound timing of asphyxial injury and neurodevelopmental outcome at two years of age. J Matern Fetal Neonatal Med. Dec 2005;18(6):361-5.

  41. Vick GW 3rd, Murphy DJ Jr, Ludomirsky A, et al. Pulmonary venous and systemic ventricular inflow obstruction in patients with congenital heart disease: detection by combined two-dimensional and Doppler echocardiography. J Am Coll Cardiol. Mar 1987;9(3):580-7. [Medline].

  42. Warnes CA. The adult with congenital heart disease: born to be bad?. J Am Coll Cardiol. Jul 5 2005;46(1):1-8.

  43. Weyman AE, Wann LS, Caldwell RL, et al. Negative contrast echocardiography: a new method for detecting left-to- right shunts. Circulation. Mar 1979;59(3):498-505. [Medline].

  44. Zanchetta M, Onorato E, Rigatelli G. Intracardiac echocardiography-guided transcatheter closure of secundum atrial septal defect: a new efficient device selection method. J Am Coll Cardiol. Nov 5 2003;42(9):1677-82.

Further Reading

Keywords

atrial septal defect, atrial septum, ASD, ostium secundum ASD, sinus venosus defect, ostium primum defect, ostium secundum defect, congenital heart disease, congenital cardiac disorder, ventricular dilatation, thoracic surgery, pulmonary hypertension, Eisenmenger syndrome, Holt-Oram syndrome, transcatheter occlusion devices, dyspnea, fatigue, palpitations, syncope, congestive heart failure, CHF

Contributor Information and Disclosures

Author

Bekir Hasan Melek, MD, Assistant Professor of Clinical Medicine, Department of Medicine, Section of Cardiology, Tulane University School of Medicine
Bekir Hasan Melek, MD is a member of the following medical societies: American Association for the Advancement of Science, American College of Cardiology, American College of Physicians, American Heart Association, American Medical Association, American Society of Echocardiography, and Louisiana State Medical Society
Disclosure: Nothing to disclose.

Coauthor(s)

James V Talano, MD, MM, FACC, Director of Cardiovascular Medicine, SWICFT Institute
James V Talano, MD, MM, FACC is a member of the following medical societies: American College of Cardiology, American College of Chest Physicians, American College of Physician Executives, American College of Physicians, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, and Society of Geriatric Cardiology
Disclosure: Nothing to disclose.

Jeffrey C Milliken, MD, Chief, Division of Cardiothoracic Surgery, University of California at Irvine Medical Center; Clinical Professor, Department of Surgery, University of California at Irvine School of Medicine
Jeffrey C Milliken, MD is a member of the following medical societies: Alpha Omega Alpha, American Association for Thoracic Surgery, American College of Cardiology, American College of Chest Physicians, American College of Surgeons, American Heart Association, American Society for Artificial Internal Organs, California Medical Association, International Society for Heart and Lung Transplantation, Phi Beta Kappa, Society of Thoracic Surgeons, Southwestern Oncology Group, and Western Surgical Association
Disclosure: Nothing to disclose.

Peter B Smulowitz, BA, University of California at Irvine School of Medicine
Disclosure: Nothing to disclose.

Medical Editor

Park W Willis IV, MD, Sarah Graham Distinguished Professor of Medicine and Pediatrics, University of North Carolina at Chapel Hill School of Medicine
Park W Willis IV, MD is a member of the following medical societies: American Society of Echocardiography
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Steven J Compton, MD, FACC, FACP, Director of Cardiac Electrophysiology, Alaska Heart Institute, Providence and Alaska Regional Hospitals
Steven J Compton, MD, FACC, FACP is a member of the following medical societies: Alaska State Medical Association, American College of Cardiology, American College of Physicians, and Heart Rhythm Society
Disclosure: Nothing to disclose.

CME Editor

Amer Suleman, MD, Consultant in Electrophysiology and Cardiovascular Medicine, Department of Internal Medicine, Division of Cardiology, Medical City Dallas Hospital
Amer Suleman, MD is a member of the following medical societies: American College of Physicians, American Heart Association, American Institute of Stress, American Society of Hypertension, Federation of American Societies for Experimental Biology, Royal Society of Medicine, and Society of Cardiac Angiography and Interventions
Disclosure: Nothing to disclose.

Chief Editor

Michael E Zevitz, MD, Assistant Professor of Medicine, Finch University of the Health Sciences, The Chicago Medical School; Consulting Staff, Private Practice
Michael E Zevitz, MD is a member of the following medical societies: American College of Cardiology, American College of Physicians, American Medical Association, and Michigan State Medical Society
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.